YiChang HEC ChangJiang Pharmaceutical Co., Ltd.
YIHCF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.10 | 0.00 | -0.39 | 0.03 |
| FCF Yield | -30.93% | 31.33% | 33.85% | -33.25% |
| EV / EBITDA | 4.08 | 1.59 | 9.02 | -24.82 |
| Quality | ||||
| ROIC | 5.16% | 19.14% | 4.74% | -5.03% |
| Gross Margin | 75.03% | 79.21% | 76.00% | 52.93% |
| Cash Conversion Ratio | 0.15 | 0.79 | 22.19 | 1.13 |
| Growth | ||||
| Revenue 3-Year CAGR | -0.19% | 90.27% | 16.84% | -47.25% |
| Free Cash Flow Growth | -201.35% | -4.58% | 210.90% | -433.67% |
| Safety | ||||
| Net Debt / EBITDA | 0.78 | 0.34 | 4.19 | -9.98 |
| Interest Coverage | 6.92 | 10.35 | 1.15 | -1.88 |
| Efficiency | ||||
| Inventory Turnover | 1.44 | 3.20 | 2.85 | 1.54 |
| Cash Conversion Cycle | 395.27 | 179.60 | 157.98 | 330.84 |